These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21424533)

  • 1. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database.
    Seto Y; Tanaka E; Inoue E; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2011 Dec; 21(6):579-93. PubMed ID: 21424533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
    Tanaka Y; Mimori T; Yamanaka H; Sunaga N; Morita K; Kimura J; Takeuchi T
    Mod Rheumatol; 2020 May; 30(3):424-433. PubMed ID: 31267801
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA).
    Yamanaka H; Inoue E; Tanaka E; Nakajima A; Taniguchi A; Terai C; Hara M; Tomatsu T; Kamatani N
    Mod Rheumatol; 2007; 17(2):98-105. PubMed ID: 17437163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
    Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
    Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate.
    Kitahama M; Nakajima A; Inoue E; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):788-93. PubMed ID: 22975732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan.
    Yamanaka H; Inoue E; Singh G; Tanaka E; Nakajima A; Taniguchi A; Hara M; Tomatsu T; Kamatani N
    Mod Rheumatol; 2007; 17(4):283-9. PubMed ID: 17694260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T;
    Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use.
    Suzuki Y; Hirose T; Sugiyama N; Nomura K; Campos-Alberto E
    Mod Rheumatol; 2021 May; 31(3):575-586. PubMed ID: 32933346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.
    Nakashima Y; Miyahara H; Kondo M; Fukuda T; Harada H; Haraguchi A; Inoue Y; Ishinishi T; Maekawa M; Maeyama A; Nakashima M; Shono E; Suematsu E; Shimauchi T; Tsuru T; Tsukamoto H; Yoshizawa S; Yoshizawa S; Iwamoto Y
    Mod Rheumatol; 2017 Jan; 27(1):15-21. PubMed ID: 27142240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.
    Takeuchi T; Rischmueller M; Blanco R; Xavier RM; Ueki Y; Atsumi T; Chen S; Friedman A; Pangan AL; Strand V; van Vollenhoven RF
    Mod Rheumatol; 2021 May; 31(3):534-542. PubMed ID: 33164611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.